Eli Lilly Boosts Investment Across U.S., Europe

Eli Lilly and Company (NYSE:LLY) (Indianapolis, Indiana) has invested more than US$20 billion since 2020 to construct and scale up its manufacturing facilities in the U.S. and Europe, according to Reuters, amid soaring demand of its top selling weight loss and diabetes drugs Zepbound and Mounjaro.

Eli Lilly aims to expand its current drug output and has announced several investment plans across U.S. and Europe, as well as start production of the recently approved Alzheimer's treatment.

Recently, the company announced plans to establish a medicine foundry in Lebanon, Indiana, for development and advanced manufacturing, which currently has an estimated value of US$4.5 billion. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project and Plant databases can learn more from a detailed project report and plant profile.

Eli Lilly is investing significantly in Europe, where it recently unveiled plans for two manufacturing facilities in Limerick, Ireland: a US$1 billion active biological ingredient (API) facility, which will manufacture the Alzheimer's drug, and four projects, totaling about US$2 billion, for a monoclonal antibody APIs plant. Subscribers can read detailed reports on the Alzheimer's API and monoclonal antibody API projects.

Industrial Info is tracking 40 active capital-spending projects globally, worth about US$22 billion, from Eli Lilly. About 77% of the spending is situated in North America, while more than 23% is in Europe. Subscribers can click here for a full list of detailed project reports and click here for a full list of related plant profiles.

Contact us for more information.

If you want more news, click here.